Acute Myeloproliferative Disease
Pp. 201-217 (17)
Eduardo Magalhaes Rego and Mariana Tereza de Lira Benicio
Acute myeloproliferative disease is a heterogeneous group of malignant disorders. In spite of
the great variability regarding genetic and clinical aspects, all forms present common mechanisms
underlying their pathogenesis: the disruption of genes tightly involved in the control of cell
differentiation, proliferation and/or apoptosis. Major progress has been made to better understand such
events and recurrent genetic abnormalities have been acknowledged based on both physiopathologic
and prognostic relevance: t(15;17), t(8;21), inv(16)/t(16;16), in addition to mutations in the genes
NPM1, FLT3 and CEBPA. These genetic alterations have identified particular subgroups of patients
and their resultant aberrant proteins have become targets for drug development, intending to improve
therapy efficacy and to diminish its toxicity.
World Health Organization Classification of AML, Acute Myeloid Leukemia with Recurrent
Genetic Abnormalities, Acute Myeloid Leukemia with Myelodysplasia-related changes, Therapy-related
Myeloid Neoplasms, Myeloid Sarcoma, Myeloid proliferations related to Down syndrome, Blastic
Plasmacytoid Dendritic Cell Neoplasm, Physiopathology of Specific Subgroups, Acute Promyelocytic
Leukemia, Core-Binding Factor AML , Cytogenetically Normal Acute Myeloid Leukemia (CN-AML),
FLT3-ITD AML, CEBPA mutated AML.
Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirao Preto, University of Sao Paulo, Av. Bandeirantes 3900, CEP 14049- 900, Ribeirao Preto, SP, Brazil.